Trial Profile
A randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT-17 study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NVALT-17
- 18 Jun 2014 New trial record